Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00125411
Status:
TERMINATED
Last Update Posted:
2012-03-26
First Post:
2005-07-28
Brief Title:
Study of Satraplatin JM-216 in Combination With Docetaxel
Sponsor:
Agennix
Organization:
Agennix
Study Overview
Official Title:
Phase I Study of the Oral Platinum Agent Satraplatin JM-216 in Combination With Docetaxel in Treatment of Advanced Malignancies
Status:
TERMINATED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor decided to discontinue study drug development
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single center open-label non-randomized Phase I dose finding study of the investigational oral cytotoxic drug satraplatin JM-216 in combination with docetaxel in patients with advanced solid tumors for whom curative therapy is not available Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria
PURPOSE The purpose of this trial is to determine a tolerable dose and schedule for the combination of satraplatin and docetaxel when given to patients with advanced solid tumors
WHAT IS SATRAPLATIN Satraplatin is an oral investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies Unlike the currently marketed platinum-based drugs satraplatin can be given orally
PURPOSE The purpose of this trial is to determine a tolerable dose and schedule for the combination of satraplatin and docetaxel when given to patients with advanced solid tumors
WHAT IS SATRAPLATIN Satraplatin is an oral investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies Unlike the currently marketed platinum-based drugs satraplatin can be given orally
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None